EFPIA Unveils Nathalie Moll as New Director General
The EFPIA has revealed the appointment of Nathalie Moll as its new director general.
The European Federation of Pharmaceutical Industries and Associations (EFPIA) has revealed the appointment of Nathalie Moll as its new director general. Currently secretary general of the European Association for Bioindustries (EuropaBio), she will join EFPIA in April 2017.
Commenting on the appointment, Joe Jimenez, President of EFPIA, said “Nathalie has an excellent track record of leadership and engagement across the life science sector. We are confident she is the right person to lead EFPIA, working with stakeholders to address the challenges faced by healthcare systems in Europe.”
Moll became secretary general of EuropaBio. Moll, currently EuropaBio’s director for agricultural biotechnology in April 2010, replacing Willy De Greef.
“I am delighted to be joining EFPIA at a time when pharmaceutical innovation is having such a dramatic effect on the lives of patients across Europe,” she said. “I look forward to working with EFPIA Members, staff and the wider research, healthcare and policy community to foster an environment that supports continued innovation and drives better outcomes for patients.”
Eric Cornut will continue to lead EFPIA as interim director general until Moll joins the organisation in April.
Philip Ward is the European Editor for Applied Clinical Trials
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Full Phase IIIb BATURA Trial Results Show Airsupra Cuts Severe Exacerbations by 47% in Mild Asthma
May 20th 2025Results from the pivotal BATURA trial show that Airsupra (albuterol/budesonide) significantly outperformed albuterol monotherapy in reducing severe asthma exacerbations and systemic corticosteroid exposure, reinforcing its role as a next-generation, anti-inflammatory rescue therapy for mild asthma patients.
